BofA Lowers PT on Medtronic (MDT) Stock

Medtronic plc (NYSE:MDT) is one of the Best Bargain Stocks to Buy in June. On June 12, BofA reduced its price objective on the company’s stock to $95 from $110 and maintained a “Buy” rating on the shares. The firm’s services team has been highlighting a lower utilization environment, and thus, the analyst became more conservative with respect to the 2027 med-tech company estimates. Also, the valuations are demonstrating the utilization risk.

The analyst opines that inflation is a hurdle in 2027 with less margin expansion for med-tech. As a result, the analyst lowered 2027 estimates throughout the firm’s larger-cap coverage where companies are exposed to utilization and inflation.

In a different update, David Roman, an analyst from Goldman Sachs, maintained a “Hold” rating on the company’s stock. The rating was due to several factors that result in Medtronic plc (NYSE:MDT)’s risk‑reward profile being fairly balanced. While the analyst sees strong top‑line momentum, with cardiovascular and neuroscience franchises continuing to gain share and offsetting the lagging areas, he also noted that earnings are not able to benefit fully. This is because of increased reinvestment, portfolio mix, etc.

Medtronic plc (NYSE:MDT) is engaged in developing, manufacturing, and selling device-based medical therapies to healthcare systems, physicians, clinicians, and patients.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.